D., Paolo Desenzani, Pantanetti, P., Romano, C., Silvio Settembrini, Sebastiano Bruno Solerte, & Gian Paolo Fadini
No single or dual-agonist compound can replicate the combined effects on appetite regulation, insulin secretion, lipolysis, and thermogenesis that retatrutide produces in research settings
Editorial refresh Practical 2026 note for Retatrutide vs CagriSema vs Survodutide For this provider comparisons page, the 2026 refresh focuses on semaglutide, tirzepatide, retatrutide, cash-pay pricing, cagrisema, survodutide so the article stays close to the question behind "Retatrutide vs CagriSema vs Survodutide"
Currently in China no GLP-1 products are included in the national or local medical insurance reimbursement lists, spurring originator companies to implement patient assistance programme and commercial insurance models to reduce OOP costs